Q-omics provides the consensus-scored KHDC1 profile across patient tissues and cancer cell-line models. KHDC1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KHDC1 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, KHDC1 RNA expression shows 17,402 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where KHDC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KHDC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KHDC1 survival associations across molecular data types. KHDC1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KHDC1 RNA expression–survival associations across cancer types. High KHDC1 expression shows unfavorable associations in KIRC, ACC, BLCA, LAML, UCEC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KHDC1 RNA expression.
This table summarizes KHDC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for KHDC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KHDC1 shows lower tumor expression in KICH, UCEC and THCA and higher tumor expression in HNSC, KIRP and LUSC. The HNSC box plot shows higher KHDC1 RNA expression in tumor versus normal tissue (log2 FC = +1.229, t-test p < 0.001).
This table shows molecular features associated with KHDC1 in patient tissues and cancer cell lines. In patient samples, KHDC1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KHDC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
